SpePharm Holding, BV, a Amsterdam, The Netherlands-based pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital market, closed a €7m equity financing.
Existing investors TVM Capital, Signet Healthcare and Paul Capital Healthcare, participated in the round.
The funds will enable the company to complete the acquisition of the worldwide (with the exception of North and South America) rights to Savene®, a product for the treatment of extravasations, or leakage out of the blood stream, of certain commonly used anticancer drugs known as anthracyclines, from TopoTarget A/S (Copenhagen, Denmark) and to finance its further growth in Europe.
At the same time, SpePharm announced a €4m secured convertible debenture from Paladin Labs, Inc. (Montreal, Canada).
FinSMEs
04/03/2010